You are here
ERS Milan 2017
Jonathan Corren: Efficacy and Safety of Tezepelumab in Adults with Severe Asthma: A randomized phase 2 study
Summary of a presentation given on September 12 at the ERS congress 2017Moderate to severe asthma in many patients remains uncontrolled despite the use of standard therapies. They might benefit from biologic therapies that inhibit specific molecular pathways, for example IgE and Th2 cytokines, including IL-4, IL-5, IL-13, and their receptors. TSLP – a new target for severe asthma therapy Thymic stromal...
More congress highlights from ERS 2017 coming soon!